Literature DB >> 27054992

Receptor combinations hone T-cell therapy.

Thomas Blankenstein1.   

Abstract

Mesh：

Year:  2016        PMID： 27054992     DOI： 10.1038/nbt.3539

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

Review 1.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Authors:  Matthias Obenaus; Catarina Leitão; Matthias Leisegang; Xiaojing Chen; Ioannis Gavvovidis; Pierre van der Bruggen; Wolfgang Uckert; Dolores J Schendel; Thomas Blankenstein
Journal:  Nat Biotechnol       Date:  2015-03-16       Impact factor: 54.908

Review 4.  Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.

Authors:  Gideon Gross; Zelig Eshhar
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

5.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Authors:  Gerald P Linette; Edward A Stadtmauer; Marcela V Maus; Aaron P Rapoport; Bruce L Levine; Lyndsey Emery; Leslie Litzky; Adam Bagg; Beatriz M Carreno; Patrick J Cimino; Gwendolyn K Binder-Scholl; Dominic P Smethurst; Andrew B Gerry; Nick J Pumphrey; Alan D Bennett; Joanna E Brewer; Joseph Dukes; Jane Harper; Helen K Tayton-Martin; Bent K Jakobsen; Namir J Hassan; Michael Kalos; Carl H June
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

6.  Targeting human melanoma neoantigens by T cell receptor gene therapy.

Authors:  Matthias Leisegang; Thomas Kammertoens; Wolfgang Uckert; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2016-01-25       Impact factor: 14.808

7.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

8.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.

Authors:  Kole T Roybal; Levi J Rupp; Leonardo Morsut; Whitney J Walker; Krista A McNally; Jason S Park; Wendell A Lim
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

Review 9.  Reassessing target antigens for adoptive T-cell therapy.

Authors:  Christian S Hinrichs; Nicholas P Restifo
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

10.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.

Authors:  Christopher C Kloss; Maud Condomines; Marc Cartellieri; Michael Bachmann; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2012-12-16       Impact factor: 54.908
  10 in total
  2 in total

Review 1.  New development in CAR-T cell therapy.

Authors:  Zhenguang Wang; Zhiqiang Wu; Yang Liu; Weidong Han
Journal:  J Hematol Oncol       Date:  2017-02-21       Impact factor: 17.388

Review 2.  Strategies for Dodging the Obstacles in CAR T Cell Therapy.

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh; Shahryar Khoshtinat Nikkhoi
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.